Brenetafusp-KIMMTRAK Combo Shows 70% Two-Year Survival in Metastatic Uveal Melanoma
IMCR is trading near its 52-week low of $27.5 (8.9% above the low).
Summary
Immunocore presented Phase 1/2 data at SITC showing brenetafusp added to KIMMTRAK in first-line metastatic uveal melanoma produced a 70% two-year overall survival rate, with median OS not reached at a median follow-up of 29 months. In 17 evaluable first-line patients the combination delivered a 29% overall response rate, 24.1-month median duration of response, 71% disease control rate and 8.1-month median PFS. The company calls this the first clinical activity shown for a combination of two T cell engagers in a solid tumor, and safety was consistent with the individual agents with no new signals. Immunocore plans a randomized Phase 2/3 trial, DUET-UVEAL, to confirm the combination in this setting. This lands alongside this morning's Q3 update, where KIMMTRAK sales slipped to $102.2M and the pivotal TEBE-AM overall survival readout moved to Q2 2027 — the pipeline data is the offsetting positive. The oral presentation is scheduled for Saturday, November 7 at 3:45 p.m. ET.
At the time of this announcement, IMCR was trading at $29.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $27.50 to $40.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.